A study conducted in Canada to estimate the prevalence of psychotropic and opioid medication use by older women diagnosed with breast cancer found a significant increase in use, especially during the active treatment phase.
A study conducted in Canada to estimate the prevalence of psychotropic and opioid medication use by older women diagnosed with breast cancer found a significant increase in use, especially during the active treatment phase. Antidepressant use, on the other hand, persisted through active treatment and into survivorship.
Breast cancer diagnosis is more common in older women, who usually present with comorbidities and associated polypharmacy. Further, age-related cognitive decline and greater susceptibility to adverse reactions from cancer-related treatments could be a source of anxiety and distress in this patient population. To complicate matters, studies have shown that antidepressant medications could interfere with the efficacy of breast cancer treatments like tamoxifen. With this in mind, the authors conducted the present study, the results of which have been published in the Journal of the National Comprehensive Cancer Network, to understand pharmacologic management of distress and pain in this high-risk group of patients.
The study followed 19,353 women over age 65 who were diagnosed with incident, nonmetastatic breast cancer in Quebec, Canada. Health data were sourced from provincial, universal health, and drug insurance plans. Psychotropic and opioid medication use was assessed across the care trajectory, from the precancer stage until the first year of survivorship.
A significant increase in medication use was observed from the precancer stage into active treatment, followed by a drop in use during the first year of survivorship. Anxiolytics, the authors write, were more commonly used across the care trajectory by the studied patient population—36.3% at baseline, 50.6% during active treatment, and 44.4% during survivorship. Antipsychotic and opioid medications saw a spike in utilization during the active treatment phase: a 4.5- and 7-fold increase compared with baseline. Antidepressant use, however, peaked during the active phase (22.4%, up from 14.7% at baseline) and then was sustained during survivorship (22.3%).
Accounting for the fact that these older women who were receiving treatment for their cancer experienced distress and pain across their care trajectory, and the risk of drug-drug interactions leading to adverse events, the authors recommend integrating psychological interventions in the treatment plan to address these women’s needs.
Reference
Syrowatka A, Chang SL, Tamblyn R, Mayo NE, Meguerditchian AN. Psychotropic and opioid medication use in older patients with breast cancer across the care trajectory: a population-based cohort study. J Natl Compr Canc Netw. 2016;14(11):1412-1419.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
2 Commerce Drive
Cranbury, NJ 08512